Oronsky B, Ma PC, Morgensztern D, Carter CA (2017) Nothing but NET: a review of neuroendocrine tumors and carcinomas. Neoplasia 19(12):991–1002. https://doi.org/10.1016/j.neo.2017.09.002

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dasari A, Shen C, Halperin D et al (2017) Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 3:1335. https://doi.org/10.1001/jamaoncol.2017.0589

Article  PubMed  PubMed Central  Google Scholar 

Modlin IM, Oberg K, Chung DC et al (2008) Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9:61–72. https://doi.org/10.1016/S1470-2045(07)70410-2

Article  CAS  PubMed  Google Scholar 

Rinke A, Müller H-H, Schade-Brittinger C et al (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol 27:4656–4663. https://doi.org/10.1200/JCO.2009.22.8510

Article  CAS  PubMed  Google Scholar 

Caplin ME, Pavel M, Ćwikła JB et al (2014) Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 371:224–233. https://doi.org/10.1056/NEJMoa1316158

Article  CAS  PubMed  Google Scholar 

Strosberg J, El-Haddad G, Wolin E et al (2017) Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med 376:125–135. https://doi.org/10.1056/NEJMoa1607427

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kwekkeboom DJ, de Herder WW, Kam BL et al (2008) Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr 3 ]octreotate: toxicity, efficacy, and survival. J Clin Oncol 26:2124–2130. https://doi.org/10.1200/JCO.2007.15.2553

Article  CAS  PubMed  Google Scholar 

Strosberg J, Wolin E, Chasen B et al (2018) Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with 177Lu-dotatate in the phase III NETTER-1 trial. J Clin Oncol 36:2578–2584. https://doi.org/10.1200/JCO.2018.78.5865

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zaknun JJ, Bodei L, Mueller-Brand J et al (2013) The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 40:800–816. https://doi.org/10.1007/s00259-012-2330-6

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hicks RJ, Kwekkeboom DJ, Krenning E et al (2017) ENETS consensus guidelines for the standards of care in neuroendocrine neoplasia: peptide receptor radionuclide therapy with radiolabeled somatostatin analogues. Neuroendocrinology. https://doi.org/10.1159/000475526

Article  PubMed  Google Scholar 

Grassi I, Nicolini S, Marini I et al (2024) Lu-PRRT used more intensively on advanced gastro-entero-pancreatic and lung neuroendocrine neoplasms: preliminary results on toxicity from a randomized study. Neuroendocrinology 115:434–445. https://doi.org/10.1159/000542328

Article  CAS  PubMed  Google Scholar 

Narendran N, Luzhna L, Kovalchuk O (2019) Sex difference of radiation response in occupational and accidental exposure. Front Genet. https://doi.org/10.3389/fgene.2019.00260

Article  PubMed  PubMed Central  Google Scholar 

Nakada D, Oguro H, Levi BP et al (2014) Oestrogen increases haematopoietic stem-cell self-renewal in females and during pregnancy. Nature 505:555–558. https://doi.org/10.1038/nature12932

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schwartz JB (2003) The influence of sex on pharmacokinetics. Clin Pharmacokinet 42:107–121. https://doi.org/10.2165/00003088-200342020-00001

Article  CAS  PubMed  Google Scholar 

Narendran N, Luzhna L, Kovalchuk O (2019) Sex difference of radiation response in occupational and accidental exposure. Front Genet 10:260. https://doi.org/10.3389/fgene.2019.00260

Article  CAS  PubMed  PubMed Central  Google Scholar 

Taliaferro LP, Agarwal RK, Coleman CN et al (2024) Sex differences in radiation research. Int J Radiat Biol 100:466–485. https://doi.org/10.1080/09553002.2023.2283089

Article  CAS  PubMed  Google Scholar 

Minczeles NS, de Herder WW, Konijnenberg MW et al (2022) Dose-limiting bone marrow toxicities after peptide receptor radionuclide therapy are more prevalent in women than in men. Clin Nucl Med 47:599–605. https://doi.org/10.1097/RLU.0000000000004203

Article  PubMed  Google Scholar 

Rolleman EJ, Valkema R, de Jong M et al (2003) Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging 30:9–15. https://doi.org/10.1007/s00259-002-0982-3

Article  CAS  PubMed  Google Scholar 

Courault P, Deville A, Habouzit V et al (2022) Amino acid solutions for 177Lu-oxodotreotide premedication: a tolerance study. Cancers (Basel). https://doi.org/10.3390/cancers14215212

Article  PubMed  Google Scholar 

Vegt E, Wetzels JFM, Russel FGM et al (2006) Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin. J Nucl Med 47:432–436

CAS  PubMed  Google Scholar 

Melis M, Bijster M, de Visser M et al (2009) Dose-response effect of gelofusine on renal uptake and retention of radiolabelled octreotate in rats with CA20948 tumours. Eur J Nucl Med Mol Imaging 36:1968–1976. https://doi.org/10.1007/s00259-009-1196-8

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vaidyanathan G, Kang CM, McDougald D et al (2018) Brush border enzyme-cleavable linkers: evaluation for reducing renal uptake of radiolabeled prostate-specific membrane antigen inhibitors. Nucl Med Biol 62:18–30. https://doi.org/10.1016/j.nucmedbio.2018.05.002

Article  CAS  PubMed  Google Scholar 

Trachsel B, Valpreda G, Lutz A et al (2023) Reducing kidney uptake of radiolabelled exendin-4 using variants of the renally cleavable linker MVK. EJNMMI Radiopharm Chem 8:21. https://doi.org/10.1186/s41181-023-00206-2

Article  PubMed  PubMed Central  Google Scholar 

Valpreda G, Trachsel B, Vogel V et al (2022) Dual MVK cleavable linkers effectively reduce renal retention of 111In-fibronectin-binding peptides. Bioorg Med Chem 73:117040. https://doi.org/10.1016/j.bmc.2022.117040

Article  CAS  PubMed  Google Scholar 

Sandström M, Garske-Román U, Granberg D et al (2013) Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment. J Nucl Med 54:33–41. https://doi.org/10.2967/jnumed.112.107524

Article  CAS  PubMed  Google Scholar 

Sundlöv A, Sjögreen-Gleisner K, Svensson J et al (2017) Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry. Eur J Nucl Med Mol Imaging 44:1480–1489. https://doi.org/10.1007/s00259-017-3678-4

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alsadik S, Gnanasegaran G, Chen L et al (2022) Safety of peptide receptor radionuclide therapy with 177Lu-DOTATATE in neuroendocrine tumor patients with chronic kidney disease. J Nucl Med 63:1503–1508. https://doi.org/10.2967/jnumed.121.263056

Article  CAS  PubMed  PubMed Central  Google Scholar 

Svensson J, Berg G, Wängberg B et al (2015) Renal function a